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PHA306 – Advanced Pharmaceutics 
DURATION 
 
Reading Time: 10 minutes 
Writing Time: 120 minutes 
 
INSTRUCTIONS TO CANDIDATES 
The exam consists of 4 Sections (A, B, C & D). All sections need to be answered in the 20-page 
booklet provided 
Section A ( 1-8): 31 marks 
Section B (1-7):  24 marks 
Section C (1-8):  31 marks 
Section D (1-6): 19 marks 
Total marks of the exam: 105 marks 
EXAM CONDITIONS 
You may begin writing from the commencement of the examination session.  The reading time indicated above is 
provided as a guide only. 
This is a CLOSED BOOK examination 
Any non-programmable calculator is permitted 
No handwritten notes are permitted 
No dictionaries are permitted 
ADDITIONAL AUTHORISED MATERIALS EXAMINATION MATERIALS TO BE SUPPLIED 
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Section A (31 marks) 
 
1. Heat sterilization is one of the common methods of sterilization. What are the factors that can increase 
the efficiency of heat inactivation?  
(4 marks) 
 
2. The time required to inactivate a specific load (bioburden) of Escherichia coli (E. coli) at 110 ⁰C is 20 
minutes. Q10 for E. coli is 2. 
I. Define Q10.  
(2 marks) 
II. What is the time required to inactivate the same load of E. coli at 120 ⁰C?  
(2 marks) 
 
3. What is the difference between “Decimal reduction time D-value” and “Thermal death time”?  
(3 marks) 
 
4. Sterilization method A has an F0 = 20 
Sterilization method B has an F0 = 30 
I. What is F0?  
(2marks) 
II. Which method is considered more effective method of sterilization?  
(2 marks) 
 
5. Organic contaminants can reduce the effectiveness of some disinfectants. What are the mechanisms 
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7. Compare between the following sterilization methods in relation to the mechanism of M.O inactivation. 
(4 marks) 





    
 
8. Mention FOUR characteristics of membrane filters.  
(4 marks) 
 
End of Section A 
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Section B (24 marks) 
1. Mention TWO advantages and TWO disadvantages to intramuscular route of administration.  
(4 marks) 
 
2. What is the meaning of “compatible via Y-site” based on the “Australian injectable drugs handbook”?  
(2 marks) 
 
3. Explain the following incompatibilities: 
 
I. Diluting diazepam injection beyond four-folds produces white precipitate.  
(2 marks) 




4. A  pharmacist  receives  a  medication  order  for  300,000  units  of penicillin  G  potassium  to  be  added  
to  500 mL of  D5W (Dextrose 5% in Water).  The directions  on  the  1,000,000-unit  package  state  that  
if  1.6 ml  of solvent  are  added,  the  constituted  solution  will  measure  2 ml.. How   many   millilitres   
of   the   constituted   solution   must   be withdrawn and added to the D5W? If the medication should be 
infused over half an hour, what is the infusion rate?  
(4 marks) 
 
5. IV admixture should be prepared using “Aseptic technique”. Define this term.  
(2 marks) 
 
6. What are the types of the laminar airflow work bench? Explain the difference between them.  
(4 marks) 
 
7. In relation to the preparation of IV admixture, what is the definition of “contamination”? What are the 
possible sources of contamination?  
(4 marks) 
 
End of Section B   
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Section C (31 marks) 
1. Mini Nutrition Assessment questionnaire (MNA) is one of the screening tools used to assess the 
nutritional status of elderly patients. Mention FOUR elements/questions used in this screening tool.  
(4 marks) 
 




3. What is the mechanism of each of the following interactions? 
I. Cations can destabilize lipid emulsion used in TPN preparation.  
(2 marks) 
II. The interaction between ciprofloxacin and enteral feeding  
(2 marks) 
 
4. What are the ideal characteristics of ophthalmic delivery systems?  
(4 marks) 
 




6. In relation to inhalation therapy, explain how particle size distribution plays an important role in 
determining the drug efficacy and toxicity.  
(3 marks) 
 




8. In SEVEN steps, explain how to use pMDIs.  
(5 marks) 
End of Section C 
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Section D (19 marks) 
1. What are the plasma data or parameters used to assess drug bioavailability?  
(3 marks) 
 




3. What are the four types of study design used to establish a bioequivalence?  
(4 marks) 
 
4. During the manufacturing of a biological drug, any modifications in certain steps can alter the product’s 




5. When a biological drug can be considered as biosimilar?  
(3 marks) 
 




End of Section D 
 
END of Exam Paper 
